AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28535235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin plus trimethoprim‐sulfamethoxazole
Number of subjects: 500
Study 28535235 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin alone
Number of subjects: 500
Study 25812064 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract (300 mg·day‐1 CurraNZ; containing 105 mg anthocyanin)
Number of subjects: 13
Study 23844168 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral levodopa
Number of subjects: 40
Study 23844168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21427147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready to Act programme (n = 322)
Number of subjects: 509
Study 21427147 — intervention group
Group type: COMPARATOR
Intervention: GP care (n = 187)
Number of subjects: 509
Study 19479496 — intervention group
Group type: EXPERIMENTAL
Intervention: Community hospital care
Number of subjects: 68
Study 19479496 — intervention group
Group type: COMPARATOR
Intervention: General hospital care
Number of subjects: 68
Study 18604074 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg/kg mixed in paracetamol syrup
Number of subjects: 60
Study 18604074 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol syrup
Number of subjects: 60
Study 15464773 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day, n=20)
Number of subjects: 40
Study 15464773 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA plus EE2 (CPA 25 mg/day on days 5-14 plus EE2 20 microg/day on days 5-25, n=20)
Number of subjects: 40
Study 15464773 — intervention group
Group type: COMPARATOR
Intervention: Finasteride
Number of subjects: 40
Study 15464773 — intervention group
Group type: COMPARATOR
Intervention: CPA plus EE2
Number of subjects: 40
Study 11270010 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum elastic bougie
Number of subjects: 0
Study 9721345 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolysis (FB) treatment in AMI patients
Number of subjects: 72
Study 9721345 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in AMI patients (without FB)
Number of subjects: 72
Study 9721345 — intervention group
Group type: COMPARATOR
Intervention: Unstable angina patients
Number of subjects: 72
Study 9721345 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammagraphy with 99mTc-MIBI-SPECT
Number of subjects: 72
Study 8040676 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage therapies (chemotherapy, hormonal therapy, combination of cytotoxic and hormonal therapies)
Number of subjects: 140
Study 8040676 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line hormonal therapy
Number of subjects: 140
Study 8040676 — intervention group
Group type: EXPERIMENTAL
Intervention: First salvage therapy
Number of subjects: 140
Study 2558254 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (or epirubicin), cyclophosphamide, vincristine (ACO or EPICO)
Number of subjects: 91
Study 2558254 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide/cisplatin (VP16/DDP)
Number of subjects: 91
Study 2558254 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic irradiation with 40 Gy
Number of subjects: 91
Study 2558254 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 91
Study 4161578 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (average 6.9 mg/kg) plus thioacetazone (average 3.4 mg/kg), daily in one dose
Number of subjects: 0
Study 4161578 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of isoniazid (average 4.5 mg/kg body-weight) plus sodium PAS (average 0.22 g/kg), daily in two divided doses
Number of subjects: 0
Study 4161578 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-phase regimen of isoniazid (average 5.5 mg/kg) plus sodium PAS (average 0.17 g/kg), daily in one dose for 6 months, followed by isoniazid alone (average 6.8 mg/kg), daily in one dose for the second 6 months
Number of subjects: 0
Study 29607472 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvastus approach
Number of subjects: 24
Study 29607472 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar approach
Number of subjects: 24
Study 28074392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (CBL) administered intramuscularly as a single daily dose of 0.1 cc/kg for 10 days, then continued weekly for 4 months.
Number of subjects: 50
Study 28074392 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard rehabilitation therapy without CBL.
Number of subjects: 50
Study 25971261 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ribavirin
Number of subjects: 0
Study 25971261 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based ribavirin
Number of subjects: 0
Study 25971261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (dosing simulations)
Number of subjects: 0
Study 25971261 — intervention group
Group type: COMPARATOR
Intervention: Thresholds for RBV‐MP concentrations
Number of subjects: 0
Study 24011102 — intervention group
Group type: EXPERIMENTAL
Intervention: Teens and Toddlers intervention (18-20 weekly sessions in pre-school nurseries)
Number of subjects: 449
Study 21343580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone activated (sound muted) for 50 minutes
Number of subjects: 47
Study 21343580 — intervention group
Group type: COMPARATOR
Intervention: Cell phone deactivated (off condition)
Number of subjects: 47
Study 19011653 — intervention group
Group type: EXPERIMENTAL
Intervention: IPAQ-A
Number of subjects: 248
Study 19011653 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer
Number of subjects: 248
Study 15950016 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (double-blind)
Number of subjects: 42
Study 15950016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind)
Number of subjects: 42
Study 12792150 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesterolone 100 mg p.o. daily
Number of subjects: 53
Study 12792150 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 160 mg p.o. daily
Number of subjects: 53
Study 12792150 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 250 mg i.m. every 21 days
Number of subjects: 53
Study 12792150 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline testosterone 1,200 mg subcutaneous implantation
Number of subjects: 53
Study 12792150 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (only in secondary hypogonadal men)
Number of subjects: 53
Study 12792150 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 53
Study 10383596 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg twice daily for 8 weeks
Number of subjects: 14
Study 10383596 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 8707338 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMPATH‐1H (humanized antibody against the CD52 antigen)
Number of subjects: 0
Study 8707338 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMPATH‐1H
Number of subjects: 0
Study 2037861 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Function Index (FFI)
Number of subjects: 87
Study 6717541 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepaid group practice (Group Health Cooperative of Puget Sound)
Number of subjects: 1580
Study 6717541 — intervention group
Group type: COMPARATOR
Intervention: Control group (prior enrollees of the Cooperative)
Number of subjects: 1580
Study 6717541 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service
Number of subjects: 1580
Study 31340801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine monotherapy
Number of subjects: 162
Study 29151272 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for managers of bars/restaurants
Number of subjects: 334
Study 25989726 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling technique (group 1)
Number of subjects: 64
Study 25989726 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (group 2)
Number of subjects: 64
Study 24938580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily for 8 weeks
Number of subjects: 97
Study 24938580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 22813436 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6mg/kg bw)
Number of subjects: 10
Study 22813436 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6mg/kg bw glucose)
Number of subjects: 10
Study 20845204 — intervention group
Group type: EXPERIMENTAL
Intervention: Embodied Conversational Agents (ECA) for automated health communication interventions
Number of subjects: 2
Study 20845204 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative computer interface systems
Number of subjects: 2
Study 17961694 — intervention group
Group type: EXPERIMENTAL
Intervention: Early umbilical cord clamping (10 seconds)
Number of subjects: 0
Study 17961694 — intervention group
Group type: COMPARATOR
Intervention: Delayed umbilical cord clamping (2 minutes)
Number of subjects: 0
Study 17602080 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin (control arm)
Number of subjects: 444
Study 17602080 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin (for low ERCC1 levels) and docetaxel plus gemcitabine (for high ERCC1 levels) (genotypic arm)
Number of subjects: 444
Study 12716265 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-50 mg/day)
Number of subjects: 652
Study 12716265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 12716265 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 652
Study 10901491 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based tobacco use prevention intervention (teacher-led, includes curriculum units for grades 3-10, teacher training, cessation materials for grades 9-12, newsletters for high school staff)
Number of subjects: 8388
Study 10901491 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified in detail)
Number of subjects: 8388
Study 9101305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (group N)
Number of subjects: 29
Study 9101305 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (group E)
Number of subjects: 29
Study 8263455 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic penicillin
Number of subjects: 80
Study 8263455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8263455 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 80
Study 3859873 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10)
Number of subjects: 12
Study 3859873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31006806 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient (MM) supplementation
Number of subjects: 1526
Study 31006806 — intervention group
Group type: COMPARATOR
Intervention: Iron-Folic Acid (IFA) supplementation
Number of subjects: 1526
Study 30243421 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive text messaging intervention for three months post-discharge (n = 29)
Number of subjects: 59
Study 30243421 — intervention group
Group type: COMPARATOR
Intervention: Control group received a thank you text message (n = 30)
Number of subjects: 59
Study 30243421 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive text messaging intervention
Number of subjects: 59
Study 30243421 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive text messaging intervention among participants who did not attend follow-up outpatient counselling
Number of subjects: 59
Study 26521128 — intervention group
Group type: EXPERIMENTAL
Intervention: Patella eversion (group A)
Number of subjects: 44
Study 26521128 — intervention group
Group type: COMPARATOR
Intervention: Patella lateral retraction (group B)
Number of subjects: 44
Study 24190578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 24190578 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg gabapentin
Number of subjects: 150
Study 24190578 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg gabapentin
Number of subjects: 150
Study 24190578 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (all dosages)
Number of subjects: 150
Study 22282746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step self-etching, extended etching time, age group 15 to 25
Number of subjects: 120
Study 22282746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-step self-etching, extended etching time, age group >= 55
Number of subjects: 120
Study 22282746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-step self-etching system
Number of subjects: 120
Study 20565316 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of topical amphotericin B (0.5 mg/mL) eye drops with subconjunctival injection of fluconazole (2 mg/mL)
Number of subjects: 48
Study 20565316 — intervention group
Group type: COMPARATOR
Intervention: Topical amphotericin B (0.5 mg/mL) eye drops alone
Number of subjects: 48
Study 19029209 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-matched sibling donor transplantation
Number of subjects: 0
Study 19029209 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological assignment trials
Number of subjects: 0
Study 19029209 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on randomization for patients without a matched sibling donor
Number of subjects: 0
Study 19029209 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical adjustments for imbalances in patient characteristics
Number of subjects: 0
Study 16022042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy applied for 30 minutes every one and one-half hours for 48 hours post-surgery.
Number of subjects: 14
Study 16022042 — intervention group
Group type: COMPARATOR
Intervention: No cryotherapy applied (control side).
Number of subjects: 14
Study 12006419 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA)
Number of subjects: 23
Study 12006419 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 23
Study 10696421 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Observed Treatment (DOT)
Number of subjects: 836
Study 10696421 — intervention group
Group type: COMPARATOR
Intervention: Self-supervised treatment (SS)
Number of subjects: 836
Study 10696421 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Observed Treatment (DOT) at district and provincial hospitals
Number of subjects: 836
Study 10696421 — intervention group
Group type: COMPARATOR
Intervention: Self-supervised treatment (SS) at district and provincial hospitals
Number of subjects: 836
Study 10696421 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Observed Treatment (DOT) at referral centres
Number of subjects: 836
Study 10696421 — intervention group
Group type: COMPARATOR
Intervention: Self-supervised treatment (SS) at referral centres
Number of subjects: 836
Study 8572663 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl 10 mg/day (open label)
Number of subjects: 310
Study 8572663 — intervention group
Group type: COMPARATOR
Intervention: Control group (not assigned to deprenyl)
Number of subjects: 310
Study 1875200 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcotrans blood salvage canister
Number of subjects: 239
Study 1875200 — intervention group
Group type: COMPARATOR
Intervention: Standard drainage system
Number of subjects: 239
Study 6195241 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine ointment
Number of subjects: 100
Study 6195241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no povidone-iodine ointment)
Number of subjects: 100
Study 29764260 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fatigue
Number of subjects: 0
Study 29764260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 0
Study 29764260 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of physical fatigue and mental stress
Number of subjects: 0
Study 29764260 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability for errors
Number of subjects: 0
Study 29764260 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability for completion time
Number of subjects: 0
Study 29764260 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability for integrated measure
Number of subjects: 0
Study 27577509 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 80 kVp tube voltage, 270 mg iodine (I)/mL contrast agent (Visipaque, GE Healthcare)
Number of subjects: 48
Study 27577509 — intervention group
Group type: COMPARATOR
Intervention: Group B: 100 kVp tube voltage, 370 mg I/mL contrast agent (Iopamiro, Bracco)
Number of subjects: 48
Study 24574444 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg before surgery, followed by 600 mg on day 1, 900 mg on day 2, and 1200 mg on days 3-5)
Number of subjects: 104
Study 24574444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 24574444 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 104
Study 22068866 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-carbohydrate diet
Number of subjects: 170
Study 22068866 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat diet
Number of subjects: 170
Study 22068866 — intervention group
Group type: COMPARATOR
Intervention: Both diets
Number of subjects: 170
Study 20663203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/simvastatin 20 mg (EZ/Simva)
Number of subjects: 199
Study 20663203 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 199
Study 17996818 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, daily symptom and self-reported weight monitoring intervention
Number of subjects: 0
Study 17996818 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16009349 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygosity for the long variant of 5HTT
Number of subjects: 2
Study 16009349 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary hypertension secondary to underlying pulmonary disease
Number of subjects: 2
Study 12021225 — intervention group
Group type: EXPERIMENTAL
Intervention: DX‐9065a (weight-adjusted regimens)
Number of subjects: 73
Study 12021225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 9560075 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish HHIE-S
Number of subjects: 100
Study 9560075 — intervention group
Group type: COMPARATOR
Intervention: English HHIE-S
Number of subjects: 100
Study 7666088 — intervention group
Group type: EXPERIMENTAL
Intervention: Western resection with limited lymphadenectomy
Number of subjects: 473
Study 7666088 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese resection with extended lymphadenectomy
Number of subjects: 473
Study 2664160 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex technique
Number of subjects: 64
Study 2664160 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard technique
Number of subjects: 64
Study 2664160 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 64
Study 177803 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 g phenformin
Number of subjects: 12
Study 177803 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.55 g metformin
Number of subjects: 12
Study 177803 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 g buformin
Number of subjects: 12
Study 177803 — intervention group
Group type: EXPERIMENTAL
Intervention: biguanide treatment
Number of subjects: 12
Study 31262580 — intervention group
Group type: EXPERIMENTAL
Intervention: Photogrammetry for mandibular movement evaluation
Number of subjects: 49
Study 31262580 — intervention group
Group type: EXPERIMENTAL
Intervention: Photogrammetry for head posture evaluation
Number of subjects: 49
Study 28257169 — intervention group
Group type: COMPARATOR
Intervention: eGFRcys <30 versus 60+
Number of subjects: 508
Study 28257169 — intervention group
Group type: COMPARATOR
Intervention: eGFRB2M <30 versus 60+
Number of subjects: 508
Study 25444354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention based on the transtheoretical model of change (TTM)
Number of subjects: 722
Study 25444354 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 722
Study 23868188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib 1.5 mg with weekly paclitaxel 90 mg/m²
Number of subjects: 18
Study 23868188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib plus weekly paclitaxel
Number of subjects: 18
Study 21619503 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infusion analgesia (LINFA) with Ropivacain, Ketorolac, and Adrenaline administered through a catheter
Number of subjects: 60
Study 21619503 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered through a catheter
Number of subjects: 60
Study 21619503 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infusion analgesia (LINFA)
Number of subjects: 60
Study 21619503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19622617 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4g/d)
Number of subjects: 25
Study 16963350 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole wheat/brown rice diet
Number of subjects: 25
Study 16963350 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley diet
Number of subjects: 25
Study 16963350 — intervention group
Group type: EXPERIMENTAL
Intervention: Half wheat-rice/half barley diet
Number of subjects: 25
Study 16963350 — intervention group
Group type: COMPARATOR
Intervention: Controlled Step I diet
Number of subjects: 25
Study 15364865 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendocardial injection of autologous bone marrow mononuclear cells (ABMMNCs)
Number of subjects: 20
Study 15364865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ABMMNC injection)
Number of subjects: 20
Study 16371892 — intervention group
Group type: EXPERIMENTAL
Intervention: OP-1 Putty (rhBMP-7)
Number of subjects: 36
Study 16371892 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest autograft
Number of subjects: 36
Study 10469292 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg)
Number of subjects: 1609